Recce Pharmaceuticals

Recce Pharmaceuticals is a global leader in synthetic polymer antibiotics. The company is developing a new broad-spectrum antibiotic targeting superbugs. It is pioneering the development and commercialization of novel synthetic antibiotics with broad activity, aiming to address the urgent global health issue of antibiotic-resistant superbugs. Its patented leading candidate drug, RECCE®327, has been developed for treating bloodstream infections and sepsis originating from E. coli and Staphylococcus aureus, including their superbug forms. To date, preclinical testing in laboratories and animal models in Australia and overseas has shown positive results.